Alphamab Oncology (HKG:9966)

Market Cap	6.92B -16.9%
Revenue (ttm)	630.11M -11.5%
Net Income	-126.79M
EPS	-0.13
Shares Out	968.57M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,541,800
Open	7.05
Previous Close	7.14
Day's Range	6.78 - 7.57
52-Week Range	6.01 - 15.75
Beta	0.49
Analysts	Strong Buy
Price Target	9.82 (+34.15%)
Earnings Date	Mar 25, 2026

About Alphamab Oncology

Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People’s Republic of China. It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antibody (BsAb) tha...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 498
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9966

Financial Performance

Financial numbers in CNY

Analyst Summary

According to one analyst, the rating for 9966 stock is "Strong Buy" and the 12-month stock price target is $9.82.

Price Target

$9.82

(34.15% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 18, 2026

Data Sources Report a data error